Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

News: Therapy Watch launches a new wave of EU tracking in Psoriasis (PsO)

A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...

Inizio

Emerging Markets: Your Essential Guide

Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...

Inizio

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...

Inizio

- PMLiVE

Horizon sunny as thyroid eye disease drug hits the mark

New treatment helps lessen eye bulging

- PMLiVE

NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access

Pressure will be maintained on costs, despite VPAS price cap deal

Bristol-Myers Squibb (BMS) building

Reluctant shareholders threaten $74bn BMS merger with Celgene

Shareholders claim merger undervalues BMS but analysts convinced the deal will close

Storm Chasers

The way people respond to tornado warnings may have public health implications

- PMLiVE

UK launches National Genomic Healthcare strategy

New initiative unveiled to coincide with Rare Disease Day

- PMLiVE

Rare Diseases Day

More than other conditions, rare diseases require a human touch, but technology can provide a vital helping hand

- PMLiVE

UCB looks to pipeline with five years left for twin blockbusters

CEO outlines pipeline promise, won't write off post-Brexit UK

- PMLiVE

Sage raises $575m ahead of FDA review date for Zulresso

Company should get verdict by 19 March

- PMLiVE

EMA could follow FDA’s Xeljanz blood clot warning

European agency in step with FDA after safety doubts

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links